NEW STUDY: ENHANCING MICROTESE SUCCESS, PROLISTEM SUPPLEMENT FOR NON-OBSTRUCTIVE AZOOSPERMIA

To evaluate the efficacy of Prolistem, a novel supplement, in enhancing MicroTESE success rates for men with non-obstructive azoospermia (NOA).

A randomized study was conducted on 40 NOA patients, divided into two groups: Prolistem (n=20) and control (n=20). The Prolistem® group received the supplement for six months before undergoing MicroTESE, while the control group received random multivitamins. Success rates of sperm extraction during MicroTESE were compared between the groups.

In the Prolistem group, 12 out of 20 patients (60%) successfully had sperm extracted during MicroTESE. In contrast, only 4 out of 20 patients (20%) in the control group achieved successful sperm extraction.

Prolistem supplementation significantly increased the success rate of sperm extraction during MicroTESE for men with NOA compared to standard multivitamins. These findings highlight the potential of Prolistem as a therapeutic intervention for improving fertility outcomes in NOA patients.

The use of Prolistem offers a promising avenue for addressing male infertility associated with NOA, potentially revolutionizing treatment approaches and offering hope to individuals struggling with this condition. Further research and clinical trials are warranted to validate these findings and explore the broader implications of Prolistem supplementation in male infertility management.